Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06092814 · ClinicalTrials.gov registry record · NA

tACS to Enhance Language Abilities

A NA study of Stroke and Aphasia, sponsored by University of Pennsylvania.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06092814 is a NA study of Stroke and Aphasia that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 120 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06092814, a NA study of Stroke and Aphasia, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to see if transcranial alternating current stimulation (tACS) can be used to enhance language abilities in people with post-stroke aphasia. Participants will receive real and sham tACS in conjunction with various language tests. Researchers will compare the post-stroke aphasia group with aged matched controls to see if brain response to tACS differs between groups.

Interventions

  • DEVICE Active transcranial alternating current stimulation (tACS)

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-07-12
Est. Completion 2028-08-31
Phase NA

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT06092814

The ClinicalTrials.gov registry entry for NCT06092814 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Active transcranial alternating current stimulation (tACS) is the first listed.

NCT06092814 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06092814 about?

NCT06092814 is a clinical study titled "tACS to Enhance Language Abilities". The goal of this study is to see if transcranial alternating current stimulation (tACS) can be used to enhance language abilities in people with post-stroke aphasia. Participants will receive real and sham tACS in conjunction with various language tests. Researchers will compare the post-stroke apha...

What is the current status of trial NCT06092814?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-07-12. Estimated completion is 2028-08-31.

What conditions does trial NCT06092814 study?

This clinical trial studies the following conditions: Stroke, Aphasia, Aphasia, Acquired.

What interventions are being tested in trial NCT06092814?

The interventions under investigation include: Active transcranial alternating current stimulation (tACS) (DEVICE).

Who is sponsoring clinical trial NCT06092814?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06092814 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.